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Treatment of Canine Heart Failure  
Tony Glaus, Prof. Dr. vet. med., Dipl. ACVIM &ECVIM-CA 
Head Division of Cardiology, Vetsuisse Faculty University of Zurich, Switzerland 
 
The following notes contain excerpts of the paper Matos J. and Glaus T. Medical treatment of 
canine heart failure. EJCAP - Vol. 20 - Issue 2 October 2010. A comprehensive reference list is 
provided there.   
 
Heart diseases are relevant clinical problems presented in practice, being estimated to 
affect around 10% of the dogs seen in first opinion veterinary practices. As “heart 
disease” or “heart failure” per se do not represent adequate diagnoses that would dictate 
or justify a specific or even cookbook treatment, as exact a diagnosis as possible should 
be made before treatment of heart failure is initiated. As an example, heart failure 
manifested as exercise intolerance combined with ascites may be the consequence of 
various congenital or acquired heart diseases, e.g. tricuspid valve dysplasia, a large 
atrial septal defect, pulmonic stenosis, tachycardia-induced dilated cardiomyopathy, 
pericardial effusion and others; however, as similar as the clinical manifestations of 
these diseases may be, as dissimilar are the individual treatment strategies. Therefore, a 
cardiac diagnosis ideally comprises the name of a specific disease from a 
comprehensive list of congenital and acquired diseases, as well as specific diagnoses of 
all aspects of the failure, including clinical aspects, i.e. forward failure and / or 
backward failure and left sided and / or right sided failure, pathophysiological aspects, 
i.e. systolic failure and / or diastolic failure, and complicating aspects, e.g. 
supraventricular and / or ventricular arrhythmias.  
The two most common acquired canine heart diseases are chronic degenerative mitral 
valve disease (CMVD) and dilated cardiomyopathy (DCM). These two diseases are the 
only ones where some randomized evidence concerning treatment has been gathered in 
canine cardiology. The following will therefore focus on treatment recommendations 
for CMVD and DCM based on evidence where available and based on logic where not, 
tailored to the stage of the disease (table). The treatment recommendations assume that 
not only has a clear diagnosis of CMVD or DCM been reached, but also a clear 
association between heart disease and presenting signs been established.  
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Drugs to treat heart failure can be divided into: Diuretics, positive inotropes, 
vasodilators, antiarrhythmics, drugs affecting remodelling, drugs modifying neuro-
endocrine activation, nutraceuticals, symptomatic cough suppressants 
 
Treatment of heart failure depending on the stage, 
CHIEF classification of heart failure 
Stage A risk of heart disease present, examples: positive gene test,  
being KKC predisposed to CMVD or Doberman to DCM 
Stage B heart disease present, asymptomatic 
  ≈ NYHA Ia  B1 normal cardiac size 
  ≈ NYHA Ib B2 enlarged atrium or ventricle 
Stage C heart failure objectively documented, present or past 
  ≈ NYHA I C1 presently asymptomatic (stable heart failure) 
  ≈ NYHA II-III C2 presently mild to moderate heart failure 
  ≈ NYHA IVa C3 presently severe heart failure 
Stage D severe heart failure, resistent to common treatment, 
  ≈ NYHA IVb needs hospitalisation and additional therapeutic measures 
 
Stages A and B 
So far, randomized studies with ACE-inhibitors (ACEI) starting in the asymptomatic 
phase of CMVD could not document a benefit in respect to delaying onset of heart 
failure. Randomized studies with Pimobendan for CMVD as well as DCM are under 
way.  
Stage C 
The first sign of CMVD is cough, which occurs in most instances long before 
congestive heart failure with pulmonary edema and associated dyspnea develops. 
Exercise intolerance is not an early sign of CMVD disease, either, and its presence 
should trigger the search for non-cardiac causes.  
Before a coughing dog with a typical murmur of mitral regurgitation is placed on 
cardiac drugs, the relevance of mitral regurgitation for the cough should be corroborated 
using radiographs and / or echocardiography. Other causes of cough like tracheal 
collaps, bronchial collapse, chronic bronchitis or interstitial lung disease should be 
ruled-out. 
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Dogs coughing associated with CMVD often times are far away from congestive heart 
failure and represent a therapeutic challenge. The symptoms in these cases are related to 
compression of the left mainstem bronchus by an enlarged left atrium and probably to 
chronic bronchial irritation due to the permanent regurgitant jet. It seems logical to try 
to reduce the volume of MR in order to decrease the size of the left atrium and bronchial 
compression, and to reduce the speed of the regurgitant jet. For this purpose, we use 
amlodipine combined with an ACEI as first approach. The developments of cough and 
of blood pressure are monitored, and amlodipine is titrated up to around 0.2 mg/kg 
q24h. If the cough is not clearly suppressed within 10 days, and if there is only 
moderate left atrial enlargement, dihydrocodein or butorphanole are added to the above 
drugs as next therapeutic trial. If the cough is not suppressed and there is severe left 
atrial dilation, furosemide instead of cough suppressants is added to the above 
treatment. If cough is still present, pimobendan is added. It has to be pointed out that no 
clinical trial, but only pathophysiological logic are the basis for this approach.  
Standard maintenance treatment of dogs with overt heart failure due to CMVD includes 
furosemide (usual dose and dose intervall of 2 mg/kg q12h titrated up or down to 
minimal effective dose), pimobendan and an ACEI, even though preliminary data did 
not show a benefit of this triple therapy compared to the combination of furosemide 
with only pimobendan. If monetary considerations are an issue, furosemide combined 
with pimobendan alone as opposed to furosemide combined with an ACEI alone is 
preferred. If the combination of high doses of furosemide per os (>3 mg/kg q8h p.o.), 
ACEI (q12h) and pimobendan (0.25 mg/kg q12h) does not control pulmonary 
congestion or ascites, the administration of furosemide is changed to s.c. and 
amlodipine is added. 
The signs of heart failure in dogs with DCM vary depending on severity of myocardial 
failure, predominating side of heart failure, etiology of myocardial failure, and presence 
of arrhythmias. As an example, in tachycardia-induced DCM often right sided 
congestion predominates. In dogs with tachyarrhythmias, ventricular tachycardia or 
atrial fibrillation, exercise intolerance and syncope may be present without overt 
congestion. Therefore, choice of drugs in the individual dog should be done based on its 
individual problems. Dogs with arrhythmias and decreased contractility but without 
congestion do not routinely receive diuretics; they are placed on antiarrhythmic drugs 
based on the exact ECG diagnosis and on pimobendan. Dogs with left sided congestive 
heart failure are treated like described for CMVD, i.e. furosemid in dose and interval to 
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effect combined with pimobendan and an ACEI. Dogs with right sided congestive heart 
failure probably do not adequately intestinally absorb drugs; in these furosemide is 
given i.v. or s.c. until the ascites is controlled. Extrapolated from human medicine, dogs 
with DCM may benefit from spironolactone.  
Stage D 
In fulminant pulmonary edema furosemide may be administered as IV bolus every 2 to 
6 hours or as IV CRI (0.6 to 1 mg/kg/h), the latter may be more effective. These dogs 
may benefit form nitrates, particularly sodium nitroprusside as CRI. Pimobendan may 
be administered by the i.v. route, if oral medication is not possible. By definition, these 
dogs need hospital care, and therefore should be referred to a hospital. 
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